<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="976">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148442</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI322A106</org_study_id>
    <nct_id>NCT05148442</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor</brief_title>
  <official_title>A Phase Ia/Ib Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study evaluating the safety, tolerability and preliminary efficacy of&#xD;
      IBI322 in Myeloid tumor patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1a/1b study will be conducted to evaluate the tolerability, safety, PK, PD,&#xD;
      immunogenicity and preliminary antitumor activity of IBI322 in patients with myeloid tumor.&#xD;
      Phase 1a is dose escalation. Phase 1b is dose expansion, and combination therapy with&#xD;
      HMA(Azacitidine or Decitabine) .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">May 21, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 19, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment related AEs</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
    <description>safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with response</measure>
    <time_frame>Last patient enrolled+24 weeks</time_frame>
    <description>preliminary efficacy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Myeloid Tumor</condition>
  <arm_group>
    <arm_group_label>IBI322</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI322+HMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI322</intervention_name>
    <description>Recombinant anti-human CD47/PD-L1 bispecific antibody</description>
    <arm_group_label>IBI322</arm_group_label>
    <arm_group_label>IBI322+HMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMA</intervention_name>
    <description>Azacitidine is a chemical analogue of the nucleoside cytidine, which is present in DNA and RNA. It is thought to have antineoplastic activity via two mechanisms - at low doses, by inhibiting of DNA methyltransferase, causing hypomethylation of DNA,and at high doses, by its direct cytotoxicity to abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA, resulting in cell death. Decitabine is a hypomethylating agent.It hypomethylates DNA by inhibiting DNA methyltransferase.</description>
    <arm_group_label>IBI322+HMA</arm_group_label>
    <other_name>Azacitidine or Decitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who met the diagnostic criteria of recurrent / refractory AML (WHO&#xD;
             2016)(primordial cells in bone marrow ≥ 5%) (excluding APL and bcr-abl positive AML )&#xD;
             and unerwent treatment.&#xD;
&#xD;
          2. Patients who meet the diagnostic criteria of recurrent / refractory MDS (WHO 2016)and&#xD;
             underwent treatment.&#xD;
&#xD;
          3. Patients with recurrent / refractory Essential thrombocythemia (WHO2016) after&#xD;
             treatment (for Phase Ia)&#xD;
&#xD;
          4. Male or female subject above 18 years old&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) performance status 0 ~&#xD;
             2.&#xD;
&#xD;
          6. Must have adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous history with myeloproliferative Neoplasms(MPN) or MDS/MPN&#xD;
&#xD;
          2. Transformation or treatment related AML/MDS.&#xD;
&#xD;
          3. PV/MF/AML/MDS eloved from Essential thrombocythemia&#xD;
&#xD;
          4. Relapse after allogeneic hematopoietic stem cell transplantation, or autologous&#xD;
             hematopoietic stem cell transplantation within 1 year&#xD;
&#xD;
          5. Central nervous system leukemia infiltration&#xD;
&#xD;
          6. Previous history of chronic hemolytic anemia or screening Coombe test positive&#xD;
&#xD;
          7. Previous exposure to any anti-CD47 monoclonal antibody, SIRPα antibody, or CD47/SIRPα&#xD;
             recombinant protein.&#xD;
&#xD;
          8. Previous exposure to chimeric antigen receptor T cell immunotherapy (CAR-T)&#xD;
&#xD;
          9. Patients who received immunotherapy, targeted therapy, biological therapy or any&#xD;
             clinical research treatment within 14 days before receiving the first dose&#xD;
&#xD;
         10. Uncontrolled concurrent diseases&#xD;
&#xD;
         11. Subjects who are allergic to the ingredients of the study drug&#xD;
&#xD;
         12. Subjects who have used immunosuppressive drugs within 7 days before the first dose of&#xD;
             study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Depei Wu, M.D.</last_name>
    <phone>0086-0512-67781856</phone>
    <email>drwudepei@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first affiliated hospital of soochow university</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Depei Wu</last_name>
      <phone>0086-0512-67781856</phone>
      <email>drwudepei@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

